[[ type === 'moc' ? 'MARKET ON CLOSE' : 'FREE WEBINAR' ]]
[[ timeLabel ]] WATCH LIVE:
Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Get all the relevant market information you need — get it fast, on time, and accurately with Barchart Plus. FREE 30 Day Trial
Stocks | Futures | Watchlist | News | More
or
Faster, Cleaner, Better.

Scinai Immunotherapeutics Ltd ADR (SCNI)

Scinai Immunotherapeutics Ltd ADR (SCNI)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
News & Headlines for [[ item.sessionDateDisplayLong ]]
Scinai Immunotherapeutics Announces $2.61 Million Private Placement Financing

JERUSALEM , April 24, 2026 /PRNewswire/ -- Scinai Immunotherapeutics Ltd. (NASDAQ: SCNI), ("Scinai" or the "Company") a biopharmaceutical company advancing a pipeline of innovative inflammation...

SCNI : 0.5703 (-8.80%)
Scinai Completes Strategic Reorganization to Establish Dedicated CDMO Platform and Lean R&D Structure; Outlines 2026 Priorities

JERUSALEM , April 6, 2026 /PRNewswire/ --  Scinai Immunotherapeutics Ltd.  (NASDAQ: SCNI); ("Scinai" or the "Company"), a biopharmaceutical company developing inflammation and immunology...

SCNI : 0.5703 (-8.80%)
Scinai Reports Full-Year 2025 Results, with CDMO Revenues Doubling and Strategic Expansion Through Recipharm Collaboration

JERUSALEM , April 1, 2026 /PRNewswire/ -- Scinai Immunotherapeutics Ltd.  (NASDAQ: SCNI); ("Scinai" or the "Company"), a biopharmaceutical company operating a dual R&D and CDMO business...

SCNI : 0.5703 (-8.80%)
Scinai Immunotherapeutics Highlights Expanded CDMO Platform and Immunology Pipeline at BIO-Europe Spring® 2026

JERUSALEM , March 19, 2026 /PRNewswire/ -- Scinai Immunotherapeutics Ltd. (Nasdaq: SCNI), a biopharmaceutical company advancing a pipeline of innovative inflammation and immunology therapeutics,...

SCNI : 0.5703 (-8.80%)
Scinai Immunotherapeutics Receives Nasdaq Notification Regarding Minimum Bid Price

JERUSALEM , March 16, 2026 /PRNewswire/ --  Scinai Immunotherapeutics Ltd.  (Nasdaq: SCNI) ("Scinai" or the "Company"), today announced that it received a written notification from...

SCNI : 0.5703 (-8.80%)
Scinai Signs Second Amendment to PinCell Option Agreement and Submits Revised €12 Million Non-Dilutive FENG Application to Advance PC111 Through Human Proof of Concept

JERUSALEM , March 2, 2026 /PRNewswire/ --  Scinai Immunotherapeutics Ltd.  (Nasdaq: SCNI);("Scinai" or the "Company"), today announced the execution of a Second Amendment to its Binding...

SCNI : 0.5703 (-8.80%)
Scinai Announces Expanded Israel Innovation Authority Support for Robotic Aseptic Fill & Finish Platform

JERUSALEM , Feb. 25, 2026 /PRNewswire/ -- Scinai Immunotherapeutics Ltd. (Nasdaq: SCNI);("Scinai", or the "Company"), today announced that, following an additional review by the Israel...

SCNI : 0.5703 (-8.80%)
Scinai Announces Completion of Acquisition of Recipharm Israel Ltd. and Strategic Commercial Collaboration with Recipharm

JERUSALEM , Feb. 17, 2026 /PRNewswire/ -- Scinai Immunotherapeutics Ltd .  (NASDAQ: SCNI) ("Scinai", or the "Company"), a biopharmaceutical company developing inflammation and immunology...

SCNI : 0.5703 (-8.80%)
Scinai CEO Amir Reichman to Co-Lead Manufacturers Association Biopharma Manufacturing Roundtable at HealthIL

JERUSALEM , Jan. 7, 2026 /PRNewswire/ -- Scinai Immunotherapeutics Ltd. (Nasdaq: SCNI); ("Scinai", or the "Company"), a biopharmaceutical company developing inflammation and immunology (I&I)...

SCNI : 0.5703 (-8.80%)
Scinai Reports Nine-Month 2025 Results as CDMO Growth Continues and NanoAbs Pipeline Advances

JERUSALEM , Dec. 2, 2025 /PRNewswire/ -- Scinai Immunotherapeutics Ltd. (Nasdaq: SCNI) ("Scinai", or the "Company"), a biopharmaceutical company developing innovative inflammation and immunology...

SCNI : 0.5703 (-8.80%)

Barchart Exclusives

Stocks Steady Before the Open as Investors Await U.S.-Iran Updates; Earnings and Economic Data on Tap
June S&P 500 E-Mini futures (ESM26) are up +0.03%, and June Nasdaq 100 E-Mini futures (NQM26) are down -0.01% this morning as investors await the outcome of diplomatic efforts aimed at ending the Iran war. Read more
Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.